Rapport Therapeutics (NASDAQ:RAPP - Get Free Report)'s share price reached a new 52-week high on Wednesday . The company traded as high as $28.16 and last traded at $28.08, with a volume of 103644 shares trading hands. The stock had previously closed at $25.88.
Wall Street Analysts Forecast Growth
RAPP has been the topic of several analyst reports. Jefferies Financial Group began coverage on shares of Rapport Therapeutics in a research report on Tuesday, July 2nd. They set a "buy" rating and a $35.00 price target on the stock. Stifel Nicolaus began coverage on Rapport Therapeutics in a research report on Tuesday, July 2nd. They set a "buy" rating and a $35.00 price target for the company. Finally, TD Cowen started coverage on Rapport Therapeutics in a research note on Tuesday, July 2nd. They issued a "buy" rating for the company.
Read Our Latest Analysis on Rapport Therapeutics
Rapport Therapeutics Trading Up 12.9 %
The business's 50 day simple moving average is $20.73.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($1.02). As a group, equities research analysts expect that Rapport Therapeutics will post -3.46 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Rapport Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC acquired a new stake in shares of Rapport Therapeutics during the 3rd quarter worth about $101,000. Sandia Investment Management LP bought a new position in Rapport Therapeutics in the 2nd quarter valued at about $116,000. Davidson Kempner Capital Management LP acquired a new stake in Rapport Therapeutics during the second quarter worth approximately $229,000. Squarepoint Ops LLC bought a new stake in shares of Rapport Therapeutics during the second quarter worth approximately $380,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Rapport Therapeutics in the second quarter valued at approximately $1,757,000.
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Stories
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
